AI Article Synopsis
- Canova enhances the immune response by activating macrophages and promoting lymphocyte growth, and its effects were tested on non-human primates treated with cyclophosphamide.
- A study involving twelve Cebus apella monkeys showed that those treated with cyclophosphamide plus Canova had a healthier white blood cell count compared to those given only cyclophosphamide.
- The research concluded that Canova reduces the harmful effects of cyclophosphamide, particularly in terms of DNA damage, indicating its potential as a protective treatment.
Article Abstract
Background: Canova activates macrophages and indirectly induces lymphocyte proliferation. Here we evaluated the effects of Canova in cyclophosphamide-treated non-human primates.
Methods: Twelve Cebus apella were evaluated. Four animals were treated with Canova only. Eight animals were treated with two doses of cyclophosphamide (50 mg/kg) and four of these animals received Canova. Body weight, biochemistry and hematologic analyses were performed for 40 days. Micronucleus and comet assays were performed for the evaluation of DNA damage.
Results: We observed that cyclophosphamide induced abnormal WBC count in all animals. However, the group treated with cyclophosphamide plus Canova presented a higher leukocyte count than that which received only cyclophosphamide. Cyclophosphamide induced micronucleus and DNA damage in all animals. The frequency of these alterations was significantly lower in the Canova group than in the group without this medicine.
Conclusions: Our results demonstrated that Canova treatment minimizes cyclophosphamide myelotoxicity in C. apella.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.fct.2012.09.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!